Here are five things to know:
1. During the quarter, Medtronic reported GAAP net loss at nearly $1.4 billion, and GAAP results include a $2.2 billion net charge related to the U.S. transition tax change, part of the U.S. tax reform.
2. Medtronic’s U.S. revenue represented 53 percent of overall revenue, hitting $3.9 billion. U.S. revenue was down 5 percent over the same period last year, while non-U.S. developed markets increased 7 percent to $2.3 billion. Emerging markets represented 15 percent of Medtronic’s revenue and increased 12 percent to $1.1 billion.
3. Spine revenue increased 1 percent in the third quarter, hitting $661 million. The BMP line revenue grew in the mid-single digit while core spine reported low-single digit declines.
4. Pain therapies revenue increased 10 percent to $33 million, returning to growth on the strength of the Intellis platform for spinal cord stimulation in addition to a growing drug pumps line.
5. Brain therapies revenue was up 13 percent to $585 million while neurosurgery grew in the low-double digits due to the StealthStation surgical navigation system and O-arm 2 surgical imaging system.
More articles on orthopedic devices:
Mazor CEO Ori Hadomi not concerned with Globus competition
Stryker achieves 95% ownership of Vexim: 5 takeaways
Zimmer Biomet, Stryker, Smith & Nephew & more: 16 device company key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
